SCCM Resource Library-Something Old, Something New, Should We Just Go to Isavu?

Video Transcription

Video Summary

The speaker, a medical professional, discusses treatment options for antifungal therapies, particularly focusing on critically ill patients. The presentation covers the pharmacology, benefits, and challenges of various antifungal agents, including Amphotericin B, echinocandins, and azoles. Amphotericin B is highlighted for its broad fungicidal activity and nephrotoxicity risks, especially in its deoxycholate form, whereas echinocandins, particularly their low drug interaction profile, are preferred for candida infections. Azoles, with their significant drug interactions and oral availability, are useful, but require careful monitoring, especially in immunocompromised patients. The speaker emphasizes the importance of personalized treatment, considering factors like patient immune status, drug interactions, and the need for aggressive dosing due to pharmacokinetic changes in critically ill patients. Empirical and definitive treatments are tailored based on these factors, with combination therapy being less supported by evidence but possible in some cases.

Asset Caption

One-Hour Concurrent Session | Deadly Fungus: Not the Last of Us Yet

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

antifungal therapies

critically ill patients

Amphotericin B

echinocandins

azoles

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.